-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Continuous proliferation is an important feature of tumor cells, so blocking the tumor cell cycle has become an important means to control tumor development.
01 Introduction to the CDK family
01 Introduction to the CDK familyCDK, which belongs to the serine/threonine protein kinase family, has been reported to have 20 different family subtypes, all of which contain a homologous sequence of PSTAIRE, and through this sequence and the corresponding regulatory subunit-cyclin (cyclin) Combines to form an active heterodimer, which participates in physiological processes such as transcription, metabolism, neural differentiation and development.
Classified by function:
One type of CDK is involved in cell cycle regulation, mainly including CDK1, CDK2, CDK4, CDK6, etc.
One type of CDK is involved in transcription regulation, mainly including CDK7, CDK8, CDK9, CDK10, CDK11 and so on.
Picture source: "Progress in Pharmacy"
In tumor cells, overexpression or overactivation of cyclin, inhibition of CDKI activity, continuous activation of upstream division signals, etc.
Image source: Bioorganic & Medicinal Chemistry Letters
Reference: doi.
02 CDK family inhibitor development strategy
02 CDK family inhibitor development strategyIn the past 10 years, great progress has been made in the development of CDK inhibitors.
The earliest CDK inhibitors developed were pan-CDK inhibitors, such as flavopiridol and seliciclib.
The presence of cysteine and lysine residues outside the standard ATP pocket has shifted researchers' attention to the development of covalent inhibitors.
Figure 2.
Image source: Bioorganic & Medicinal Chemistry Letters
https://doi.
03 Allosteric & Covalent & Degradable & Reversible
03 Allosteric & Covalent & Degradable & Reversible☆ Allosteric inhibitor
Currently, it is mainly in the preclinical stage.
☆ Covalent inhibitor
Covalently bound CDK inhibitors are definitely a hot spot of development in recent years.
☆ Targeted degradation
By enhancing the ubiquitination of CDK protein, it induces its mediated degradation of the proteasome, thereby inhibiting protein function.
☆ Reversible competitive inhibitor
HTS is usually used to obtain CDK reversible competitive inhibitors, especially the most popular CDK4/6 inhibitors, and the focus of development is still on activity, selectivity and brain permeability.
04Conclusions and Prospects
04Conclusions and ProspectsIn the past ten years, the drug discovery in the field of CDK inhibitors has made great progress, especially the selective dual CDK4/6 inhibitors have shown strong clinical efficacy and safety.
reference:
1.
The development of CDK inhibitors in the field of anti-tumor.
"Progress in Pharmacy"
2.
European Journal of Medicinal Chemistry.
doi.
org/10.
1016/j.
ejmech.
2019.
01.
003
3.
Bioorganic & Medicinal Chemistry Letters.
doi.
org/10.
1016/j.
ejmech.
2019.
01.
003.